SpliSense Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$13M
- Investors
-
5
SpliSense General Information
Description
Developer of a novel drug designed to heal splicing mutations in genetic diseases. The company's drug candidates are based on antisense oligonucleotides, focusing on mutations in the CFTR gene, enabling medical practitioners to effectively treat cystic fibrosis.
Contact Information
Website
www.splisense.comCorporate Office
- Biohouse Labs, Minrav Building 1st Floor
- Haddasah Ein Karem
- Jerusalem 9112101
- Israel
Corporate Office
- Biohouse Labs, Minrav Building 1st Floor
- Haddasah Ein Karem
- Jerusalem 9112101
- Israel
SpliSense Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 16-Jun-2026 | $13M | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series B) | 13-May-2021 | Completed | Clinical Trials - Phase 2 | |||
| 4. Seed Round | 01-Feb-2020 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 01-Nov-2018 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 01-Jan-2017 | $400K | Completed | Startup | ||
| 1. Accelerator/Incubator | Completed | Startup |
SpliSense Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred B2 | ||||||||
| Preferred B1 | ||||||||
| Preferred A | 2,000,000 | $null | $3.03 | $3.03 | 1x | $3.03 | 15.66% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
SpliSense Comparisons
Industry
Financing
Details
SpliSense Competitors (1)
One of SpliSense’s competitors is Ultragenyx Pharmaceutical, a Formerly VC-backed company based in Novato, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical | Formerly VC-backed | Novato, CA |
SpliSense Patents
SpliSense Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025052391-A1 | Antisense oligonucleotides targeting the cftr 3849+10 kilobase (kb) c->t splicing mutation | Inactive | 06-Sep-2023 | ||
| CA-3238565-A1 | Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b | Pending | 09-Dec-2021 | ||
| EP-4426840-A1 | Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b | Pending | 09-Dec-2021 | ||
| EP-4426840-A4 | Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b | Pending | 09-Dec-2021 | ||
| WO-2023105527-A1 | Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b | Inactive | 09-Dec-2021 | C12N15/113 |
SpliSense Signals
SpliSense Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biotel Limited | Corporation | Minority | ||
| Israel Biotech Fund | Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| Integra Holdings | Venture Capital | Minority | ||
| Cystic Fibrosis Foundation | Limited Partner | Minority |
SpliSense FAQs
-
When was SpliSense founded?
SpliSense was founded in 2016.
-
Where is SpliSense headquartered?
SpliSense is headquartered in Jerusalem, Israel.
-
What is the size of SpliSense?
SpliSense has 17 total employees.
-
What industry is SpliSense in?
SpliSense’s primary industry is Drug Discovery.
-
Is SpliSense a private or public company?
SpliSense is a Private company.
-
What is SpliSense’s current revenue?
The current revenue for SpliSense is .
-
How much funding has SpliSense raised over time?
SpliSense has raised $56M.
-
Who are SpliSense’s investors?
Biotel Limited, Israel Biotech Fund, OrbiMed, Integra Holdings, and Cystic Fibrosis Foundation have invested in SpliSense.
-
Who are SpliSense’s competitors?
Ultragenyx Pharmaceutical is a competitor of SpliSense.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process